ENV-6946 / Enveda Biosci - LARVOL DELTA

Enveda, a clinical-stage biotech pioneering a new generation of small-molecule drugs, has announced that the US FDA has cleared its Investigational New Drug (IND) application for a first-in-class oral therapy for Inflammatory Bowel Disease (IBD). (Indian Pharma Post) - "Following this clearance, Enveda has officially initiated a Phase 1 clinical trial for ENV-6946."

IND • New P1 trial • Inflammatory Bowel Disease